Located less than two miles from Upperton's current headquarters in Nottingham, the site houses ten new GMP manufacturing suites, quality control laboratories and formulation development pilot plants.

The new site, Upperton stated, provides it with a manufacturing footprint increase from 1,300 square foot to 13,000 square foot, and a significant expansion of analytical laboratory space, from 880 square foot to 8,500 square foot. The facility has the capability to handle highly potent and controlled drugs in a range of dosage forms, and support early formulation development, clinical trial supplies from Phase 1 to Phase 3, and niche-scale commercial manufacture.

Nikki Whitfield, Upperton’s CEO, commented: “We are delighted with the progress of our Nottingham facility since we first began on this journey in January 2023. This build completion is a significant milestone for us and represents our significant growth as a company.”

The company’s goal is to have the new facility fully operational for development and non-GMP manufacturing by the fourth quarter of 2023, with an anticipated start of GMP operations in January 2024.